Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone(vitamin K1) mixed micelles formulation

British Journal of Clinical Pharmacology

Volumn 41, Issue 6, 1996, Pages 517-523

  Soedirman, J R ^b   De Bruijn, E A ^b,c   Maes, R A A ^b   Hanck, A ^a   Gruter J ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

intramuscular; intravenous; pharmacokinetics; phylloquinone(vitamin K1); tolerance

Indexed keywords

PHYTOMENADIONE;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TOLERANCE; FEMALE; FLUOROMETRY; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICELLE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VITAMIN BLOOD LEVEL;

EID: 0029943963     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03847.x     Document Type: Article

References (22)

1. Olson RE. The function and metabolism of vitamin K. Ann Rev Nutr 1984; 4: 281-337.
2. Suttie JW, Vitamin K. In The fat soluble vitamins, ed Diplock AT. London, Heinemann Ltd. 1985; 225-311.
3. Shearer MJ, Mc Burney A, Barlchan P. Studies on absorption and metabolism of phylloquinone (vitamin K) in man. Vitam Horm 1974; 32: 513-542.
4. Tönz O, Schubiger G. Neonatale vitamin-K-Prophylaxe und vitamine-K Mangelblutungen in der Schweiz von 1986-1988. Schweiz Med Wochenschr 1988; 118: 1747-1752.
5. Hanawa Y, Maki M, Murata B, Matsuyama E, Yamamoto, Y. The second nation-wide survey in Japan of vitamin K deficiency in infancy. Eur J Pediatr 1988; 147: 472-477.
6. Radford SG, Lockyer JA, Simpson PJ. Immunological aspects of adverse reactions to althesin. Br J Anaesth 1982; 54: 859-864.
7. Lorenz N, Reimann MJ, Schmal A. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7: 63-67.
8. Barash P, Kitahata LM, Mandel S. Acute cardiovascular collapse after intravenous phytonadione. Anaesth Analg 1976; 55: 304-306.
9. Steffen H, Schmidt. US Patent 4158707 Chem Abstr 1979; 91: 96642p.
10. 1. Med Biol 1982; 60, 16-24.
11. 1) by bile salts and phosphatidylcholine-bile salts mixed micelles. J Pharm Pharmacol 1988; 40: 85-88.
12. 1 and its procoagulant effect in anticoagulated rabbits. J Pharm Pharmacol 1989; 41: 257-260.
13. 1 after intravenous and oral administration to subjects on phenprocoumon therapy. Int J Pharmacol 1988; 48: 223-230.
14. 1 in children with cholestasis. J Pediatr Gastroenterol Nutr 1992; 14: 160-165.
15. 1 in human plasma by reversed phase high-performance liquid chromatography using fluorometric detection after post-column electrochemical reduction. Comparison with ultraviolet, single and dual electrochemical detection. J Chromatogr Biomed Appl 1984; 305: 61-72.
16. Gibaldi M, Perrier D. Pharmacokinetics, second edition, New York: Marcel Dekker, 1982.
17. Francis RJ. ELSMOS. -An extended least squares modelling system in Fortran 77 for mini- or micro-computer implementation. Comp Prog Biomed 1984; 18: 43-50.
18. 1 in relation to anticoagulant poisoning. Br J Clin Pharmacol 1984; 18: 655-662.
19. 1) metabolism in relation to pharmacodynamic response in anticoagulated patients. Br J Clin Pharmacol 1985; 20: 643-648.
20. 1. J Pharmacol Exp Ther 1979; 210: 322-326.
21. 1 -Stoffwechsel beim Menschen. Habilitationsschrift, Universität Mainz, Mainz, FRG, 1985.
22. De Bruijn EA, Van Oosterom AT, Slee PHThJ, Lameijer DW, Roozendaal KJ, Tjaden UR. Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharm Weekbl Sci Ed 1988; 10: 200-206.